Is Bristol-Myers Squibb into self-sabotage? Is Congress coming for Gut Guy? And why does Goldman Sachs love money so much?

Why are biotech investors suddenly so exuberant? What does it mean when a CEO scrubs his LinkedIn profile? And can CRISPR turn your dog into a winged hellhound bent on destroying Chicago?

What's it like to be a biotech investor? Do you know where your genetic data are? And what does it mean when the FDA swipes left on your drug?

Why aren't pharma CEOs getting hauled into Congress? Which biotech companies got a failing grade this quarter? And why is there no Kelley Blue Book for the price tag of a medicine?

What’s it like to watch gene therapy happen? Is the next big cancer clinical trial going to work? And is “right to try” going to defang the FDA?

Did Elizabeth Holmes get off easy? Why does biotech bother with SXSW? And what does shoving a tube into a dead cow’s throat have to do with biotech?

How long is Martin Shkreli going to be in prison? Is the biotech bubble about to burst? And what's it like to attend a blood-swapping gala? Listen to our first episode of, "The Readout LOUD."

An introduction to a new weekly biotech podcast from STAT.